Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613731 | 0.77 | TOP2A (0.34) | TOP2A | |
| SCHEMBL13613732 | 0.77 | TOP2A (0.34) | TOP2A | |
| SCHEMBL26045071 | 0.77 | TOP2A (0.34) | TOP2A | |
| SCHEMBL850669 | 0.74 | ALDH1A1 (0.36) | TOP2ADUT | |
| SCHEMBL850670 | 0.74 | ALDH1A1 (0.36) | TOP2ADUT | |
| SCHEMBL5676651 | 0.74 | PDK2 (0.37) | TOP2ADUT | |
| SCHEMBL5676774 | 0.74 | PDK2 (0.37) | TOP2ADUT | |
| SCHEMBL22029081 | 0.74 | PDK2 (0.37) | TOP2ADUT | |
| SCHEMBL15754838 | 0.72 | FKBP1A (0.30) | — | |
| SCHEMBL372074 | 0.72 | ERBB2 (0.38) | TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394970-B2 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO., INC. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-7674915-B2 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO., INC. (JP) | 2010-03-09 | — | — | US | disclosed |
| US-20100010234-A1 | PROCESS FOR MANUFACTURING A GLUTAMIC ACID DERIVATIVE AND A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE IN THE MANUFACTURE THEREOF | AJINOMOTO CO. INC (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010234-A1 | PROCESS FOR MANUFACTURING A GLUTAMIC ACID DERIVATIVE AND A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE IN THE MANUFACTURE THEREOF | PTMA, GRIK5, GLUL | TOP2A 988/4885DUT 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.